Combination of two target agonists of the thrombopoietin and thrombopoietin receptor in the treatment of elderly patients with refractory immune thrombocytopenia  

作　　者：Jundong Zhang Zining Wang Haoran Chen Xuechun Lu 

机构地区：[1]Department of Hematology,The Second Medical Center,Chinese PLA General Hospital Beijing,National Clinical Research Center for Geriatric Disease,Beijing 100853,China [2]Medical School of Chinese PLA,Beijing 100853,China [3]Management School,Shanxi Medical University,Taiyuan,Shanxi 030002,China

出　　处：《Cancer Pathogenesis and Therapy》2023年第2期154-156,共3页癌症发生与治疗（英文）

基　　金：supported by the National Key Research and Development Program of China(No.2020YFC2002706);the Army Health Care Special Project(No.19BJZ28).

摘　　要：Immune thrombocytopenia(ITP)is common in the elderly.Because of the coexistence of multiple diseases,there are many reservations regarding corticosteroid use in the elderly.Thrombopoietin(TPO)and its analogs can promote platelet production,but it is often difficult to correct TP in a short period.Recombinant human TPO(rh-TPO)acting on the cell membrane and the small-molecule TPO-receptor(MPL)agonist acting on the transmembrane receptor may have synergistic effects and accelerate platelet production because of different sites of action in the signaling pathway.In this study,two elderly patients with refractory ITP were successfully treated with two TPO-MPL signaling pathway agonists:recombinant human thrombopoietin(rh-TPO)and eltrombopag.This combination is safe with rapid and lasting effects.However,in elderly patients with refractory,recurrent,and glucocorticoid contraindications,the combination of different TPO agonists'clinical efficacy and adverse reactions needs to be further evaluated.

关 键 词：Immune thrombocytopenia(ITP) TPO-MPL signaling Pathway rh-TPO ELTROMBOPAG 

分 类 号：R730.5[医药卫生—肿瘤]